Uremic toxicity and sclerostin in chronic kidney disease patients.

@article{Desjardins2014UremicTA,
  title={Uremic toxicity and sclerostin in chronic kidney disease patients.},
  author={Lucie Desjardins and Sophie Liabeuf and Rodriguo B Oliveira and Lo{\"i}c Louvet and Sa{\"i}d Kamel and H. Lemke and Raymond Camille Vanholder and Gabriel Choukroun and Ziad Andr{\'e} Massy},
  journal={Nephrologie & therapeutique},
  year={2014},
  volume={10 6},
  pages={463-70}
}
BACKGROUND AND AIMS Sclerostin is a circulating inhibitor of the Wnt/β-catenin pathway and may have a role in chronic kidney disease (CKD)-mineral and bone disorder. Blood sclerostin levels are known to be elevated in patients undergoing maintenance dialysis. The aims of the present study were to evaluate sclerostin levels in patients at different CKD stages and study potential associations between sclerostin levels and (i) biochemical parameters that are disturbed in CKD, (ii) markers of… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 23 extracted citations

Similar Papers

Loading similar papers…